A three-drug regimen containing the CTLA4 inhibitor tremelimumab plus the PD-L1 inhibitor durvalumab and chemotherapy may be an effective first-line treatment strategy for patients with metastatic non–small cell lung cancer. In the phase III POSEIDON trial, the combination significantly extended progression-free survival and overall survival compared with chemotherapy alone.

You do not currently have access to this content.